Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. NERV

(NERV)

0.00

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
6.18$
Day's range
5.96 - 6.5$
52-week range
1.15 - 12.46$
Volume
167 779
Average volume
620 647
Beta
1.65
EPS (TTM)
-26.8
PE ratio (TTM)
N/A
Market cap
267 435 776
Shares outstanding
43 274 397
Dividend yield
N/A
Next earnings date
2026-05-06
Sector
Healthcare
Industry
Biotechnology

About the company

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burling... read more
CEO
Remy Luthringer
Country
United States
IPO Date
2014-07-01
Employees
7
Fiscal Year End
January - December
Website
https://www.minervaneurosci...

Revenue Breakdown

Central Nervous System Diseases Treatment / 100.00%

News

No Data

There are no news for this stock.

Chart: NERV

Loading Chart...

Overall Score

2.9 / 1029%
Financial Strength
5
Profitability
1
Effectiveness
1.8
Growth
4.6
Forecast
5.3
Valuation
3.3

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio36.286.0510
Quick ratio36.285.6310
Debt to EquityN/A0.301.0
Debt to Assets0.661.043.0
Interest coverageN/A-16.911.0
Weighted average score5.0

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2022202320242025TTM
Total RevenueN/AN/AN/AN/AN/A
Gross Profit-9K-31K-22K-5K-5K
Operating Income-25M-23M-22M-15M-15M
Net Income-32M-30M1M-293M-293M
EBITDA-25M-23M-22M-15M-15M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %N/A-11.731.0
Operating margin %N/A-24.601.0
Net margin %N/A-172.201.0
EBITDA margin %N/A-201.271.0
Cash flow margin %N/A-156.391.0
Weighted average score1.0

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-107.40-57.97
1.0
ROEN/A-63.56
1.0
ROIC1.82-42.57
4.0
ROCE-10.29-71.10
1.0
Weighted average score1.8

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarterN/A73.945.5
Next quarterN/A57.835.5
Current yearN/A61.115.5
Next yearN/A14.974.5
Weighted average score5.3

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q999-10237.92-77.77-53.653.3
Y/Y999-6540.08-14.2813.285.0
3y average999-6793.76-322.4312.915.0
5y average779.2-4603.41-674.2913.155.0
Weighted average score4.6

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/E2.57-5.25
10
PEG (5yr expected)N/A0.27
1.0
P/SN/A64.66
1.0
P/BN/A2.96
1.0
Weighted average score3.3

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price6.18$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$6.18

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Company's cash reserves $82.4M significantly exceed its total debt $65.0M, ensuring strong financial flexibility

Total current assets $83.1M exceed Total current liabilities $2.3M, highlighting excellent liquidity

Debt-to-equity ratio (-0.5) is well below the industry average (0.3), showcasing prudent financial management

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Negative free cash flow -$4.5M limits the company's ability to reinvest or pay down debt